Ryo Koyama

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

Asef, a Link Between the Tumor Suppressor APC and G-Protein Signaling

Yoshihiro Kawasaki, Takao Senda, Takao Ishidate et al. · Science · 2000 · 349 citations

Identification of a link between the tumour suppressor APC and the kinesin superfamily

Takeshi Jimbo, Yoshihiro Kawasaki, Ryo Koyama et al. · Nature Cell Biology · 2002 · 301 citations

Protein Function, Medicine, Receptor Tyrosine Kinase +7

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

Kazuhiko Nakagawa, Toyoaki Hida, Hiroshi Nokihara et al. · Lung Cancer · 2019 · 143 citations

J-alex Study, Medicine, Pathology +6

Reaction cross sections at intermediate energies and Fermi-motion effect

M. Takechi, M. Fukuda, M. Mihara et al. · Physical Review C · 2009 · 123 citations

Experimental Nuclear Physics, Nuclear Physics, Physics +13